Personalized Medicine and Targeted Therapeutics Market Research Report, Analysis and Forecast

Emerging Trends in the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market is experiencing a remarkable paradigm shift fueled by a combination of advanced biotechnology, data-driven diagnostics, and patient-centric treatment models. For instance, increasing genomic research has expanded the identification of biomarkers, enabling therapies to be tailored precisely to patient profiles. The Personalized Medicine and Targeted Therapeutics Market has been steadily shaped by the rising incidence of cancer, which alone accounted for more than 19 million new cases globally in 2024, creating a fertile ground for innovative treatment pathways. Moreover, the introduction of high-throughput sequencing and digital health platforms has created a powerful ecosystem that supports the Personalized Medicine and Targeted Therapeutics Market, advancing it far beyond traditional one-size-fits-all methods. 

Technological Breakthroughs Driving the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market has benefited enormously from a wave of disruptive technologies such as CRISPR-based genome editing, artificial intelligence-powered diagnostic tools, and companion diagnostics. For example, CRISPR technology is now being leveraged to correct genetic mutations at the root cause, pushing the Personalized Medicine and Targeted Therapeutics Market into previously uncharted treatment territory. According to Datavagyanik, digital twins are also gaining traction as a virtual testing bed for personalized drugs, enhancing precision while cutting development timelines by as much as 40%. Additionally, smart drug delivery systems such as nanoparticle carriers have significantly improved targeted drug efficacy, bolstering the Personalized Medicine and Targeted Therapeutics Market. 

Growing Demand for Oncology Solutions in the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market is particularly witnessing exponential growth in oncology applications. For instance, targeted therapeutics like HER2 inhibitors for breast cancer or EGFR inhibitors for lung cancer have reported treatment success rates of up to 60%, compared to less than 30% with traditional chemotherapy. Datavagyanik notes that oncology alone represented over 35% of the entire Personalized Medicine and Targeted Therapeutics Market Size in 2024, and is projected to maintain a robust growth trajectory. This momentum is supported by the surge in companion diagnostics, which are expected to cross USD 12 billion in valuation by 2026, further reinforcing the Personalized Medicine and Targeted Therapeutics Market. 

Chronic Disease Management Fueling the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market is equally thriving in chronic disease management beyond cancer. For example, diabetes, which affects over 537 million adults globally, is being targeted through personalized pharmacogenomic testing to optimize therapeutic regimens and reduce adverse drug reactions. Datavagyanik observes that demand for individualized cardiovascular treatments has also grown sharply, driven by precision-targeted lipid-lowering therapies and personalized anti-coagulants. These approaches have demonstrated a reduction in hospitalization rates by nearly 25%, providing strong incentives for healthcare systems to embrace the Personalized Medicine and Targeted Therapeutics Market in chronic care pathways. 

Regulatory Support Empowering the Personalized Medicine and Targeted Therapeutics Market 

An enabling regulatory framework is another crucial pillar for the Personalized Medicine and Targeted Therapeutics Market. Agencies across major markets have accelerated approvals for targeted therapies, shortening the typical drug-to-market cycle by 30–40% for biomarker-based drugs. For instance, the FDA has introduced Real-Time Oncology Review to fast-track approvals of precision oncology therapeutics. Datavagyanik underlines that such policy movements create a fertile ecosystem for market expansion, removing many previous bottlenecks that stifled innovation. As a result, the Personalized Medicine and Targeted Therapeutics Market has seen an influx of mid-tier biotech companies alongside traditional pharmaceutical giants, driving broader competition and innovation. 

Precision Diagnostics: A Catalyst for the Personalized Medicine and Targeted Therapeutics Market 

Precision diagnostics are acting as a powerful catalyst for the Personalized Medicine and Targeted Therapeutics Market. With next-generation sequencing costs dropping below USD 200 per genome, patient profiling has become accessible and scalable. For instance, the number of genetic tests globally is forecast to grow at a CAGR of over 15% through 2030, directly feeding into the Personalized Medicine and Targeted Therapeutics Market. Datavagyanik reports that companion diagnostics are increasingly being bundled with therapeutic solutions, ensuring that only the most suitable patients are treated, thereby improving cost-efficiency and clinical outcomes across the Personalized Medicine and Targeted Therapeutics Market. 

Consumer Awareness Bolstering the Personalized Medicine and Targeted Therapeutics Market 

A shift in consumer behavior is also reshaping the Personalized Medicine and Targeted Therapeutics Market. Today’s patients are better informed about precision therapies, driving demand for individualized care. For instance, a recent market observation shows that over 70% of oncology patients inquire about biomarker-based therapies during diagnosis, up from just 20% a decade ago. This dramatic rise is transforming the Personalized Medicine and Targeted Therapeutics Market into a patient-driven ecosystem where healthcare providers must adapt to deliver more personalized treatment roadmaps. Datavagyanik asserts that this level of patient engagement will remain a primary force sustaining growth in the Personalized Medicine and Targeted Therapeutics Market. 

Strategic Partnerships Strengthening the Personalized Medicine and Targeted Therapeutics Market 

Strategic collaborations have emerged as a critical enabler of innovation in the Personalized Medicine and Targeted Therapeutics Market. Pharmaceutical companies, academic research centers, and digital health innovators are increasingly pooling resources to accelerate product development. For example, major pharma alliances have invested nearly USD 4 billion in co-development of targeted immunotherapies since 2022, helping expand the Personalized Medicine and Targeted Therapeutics Market portfolio. Datavagyanik notes that these partnerships can reduce development costs by up to 35% while increasing market reach, ensuring faster patient access to advanced therapeutics. 

Personalized Medicine and Targeted Therapeutics Market Size Outlook 

The Personalized Medicine and Targeted Therapeutics Market Size was valued at approximately USD 325 billion in 2024 and is anticipated to grow beyond USD 550 billion by 2030, reflecting a CAGR exceeding 8% according to Datavagyanik. Such a robust growth trajectory is underpinned by the strong performance of oncology, neurology, rare disease treatment, and autoimmune disorders within the Personalized Medicine and Targeted Therapeutics Market. The market’s dynamic is expected to remain resilient, supported by growing R&D investments and digital transformation across the global healthcare landscape. 

Advancing Neurological Therapies in the Personalized Medicine and Targeted Therapeutics Market 

Neurological disorders are emerging as the next big frontier for the Personalized Medicine and Targeted Therapeutics Market. For instance, Alzheimer’s disease affects over 55 million people worldwide, and traditional therapies have struggled to deliver meaningful results. However, targeted monoclonal antibodies and amyloid-beta inhibitors have shown a 30% improvement in cognitive decline mitigation during early-stage trials, according to Datavagyanik. This progress is unlocking new opportunities within the Personalized Medicine and Targeted Therapeutics Market and is expected to expand dramatically as biomarker identification for neurological conditions becomes more advanced. 

Expanding Role of Artificial Intelligence in the Personalized Medicine and Targeted Therapeutics Market 

Artificial intelligence is fundamentally transforming the Personalized Medicine and Targeted Therapeutics Market by enabling advanced data analytics, predictive modeling, and precision drug discovery. For instance, AI-driven drug discovery platforms can reduce the lead optimization timeline by nearly 50%, accelerating innovation across the Personalized Medicine and Targeted Therapeutics Market. Datavagyanik highlights that machine learning models are increasingly used to predict adverse drug reactions in individual patients, which minimizes trial failures and enhances safety outcomes. These technological advantages will continue to strengthen the market’s long-term growth. 

Personalized Medicine and Targeted Therapeutics Market in Rare Diseases 

The rare disease segment is a powerful growth lever for the Personalized Medicine and Targeted Therapeutics Market. For example, over 400 million people globally live with rare diseases, many of which lack effective treatment options. Personalized therapeutics such as enzyme replacement therapies or gene therapies are gaining momentum, with approvals in rare indications growing at a CAGR of more than 10% since 2020. Datavagyanik emphasizes that as more orphan drug designations are granted, the Personalized Medicine and Targeted Therapeutics Market will see an even stronger influx of innovative solutions addressing high unmet needs. 

Market Access Challenges in the Personalized Medicine and Targeted Therapeutics Market 

Despite its enormous potential, the Personalized Medicine and Targeted Therapeutics Market also faces notable challenges. High treatment costs, fragmented reimbursement systems, and the complexity of biomarker validation can limit broad patient access. For instance, some precision oncology therapies exceed USD 100,000 per course, creating affordability pressures. Datavagyanik points out that payers and policymakers will need to design value-based reimbursement models to ensure that the Personalized Medicine and Targeted Therapeutics Market can achieve its full promise without compromising healthcare equity. 

Personalized Medicine and Targeted Therapeutics Market: Future Prospects 

The Personalized Medicine and Targeted Therapeutics Market holds extraordinary promise for reshaping global healthcare by shifting from trial-and-error therapies to data-backed, patient-specific interventions. For example, multi-omics profiling and advanced pharmacogenomics are already redefining how therapies are matched to patients, while digital therapeutics are expanding beyond drug-based interventions. Datavagyanik expects that by 2035, more than half of all approved drugs could have a companion diagnostic, further solidifying the Personalized Medicine and Targeted Therapeutics Market as a mainstream pillar of modern medicine. 

 

Regional Dynamics in the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market is witnessing distinct growth trajectories across major regions, underpinned by robust investments, healthcare infrastructure, and regulatory readiness. North America has maintained its leadership position, driven by its advanced biopharmaceutical ecosystem and a growing emphasis on precision oncology. For example, the United States alone accounted for over 45% of the Personalized Medicine and Targeted Therapeutics Market in 2024, largely supported by reimbursement models that favor companion diagnostics and advanced therapies. Datavagyanik highlights that precision oncology prescriptions in North America have grown by 12% annually over the past five years, showcasing the region’s willingness to adopt individualized therapeutic strategies. 

European Personalized Medicine and Targeted Therapeutics Market 

In Europe, the Personalized Medicine and Targeted Therapeutics Market has expanded significantly thanks to coordinated policy frameworks and funding under the Horizon Europe program. For instance, biomarker-driven therapies for rare diseases have been strongly supported across Germany, France, and the United Kingdom, where national health systems have created special pathways for early patient access. Datavagyanik estimates that Europe’s share of the Personalized Medicine and Targeted Therapeutics Market will continue to grow at 9% CAGR through 2030, with a particularly strong demand in neurology and metabolic disorders. Furthermore, digital health adoption has made personalized treatment pathways more accessible for rural and underserved areas, widening the Personalized Medicine and Targeted Therapeutics Market footprint. 

Asia Pacific Growth Trajectory in the Personalized Medicine and Targeted Therapeutics Market 

Asia Pacific is emerging as a highly dynamic contributor to the Personalized Medicine and Targeted Therapeutics Market. For example, countries like China and Japan have rapidly scaled their genetic testing capabilities, with China’s precision medicine initiative alone drawing investments exceeding USD 3 billion since 2020. Datavagyanik reports that Personalized Medicine and Targeted Therapeutics demand in Asia Pacific has surged, with oncology testing volumes increasing 18% per year in China alone. In Japan, rare disease treatment frameworks have advanced in parallel with its robust geriatric healthcare system, creating significant opportunities for personalized neurodegenerative therapies within the Personalized Medicine and Targeted Therapeutics Market. 

Middle East and Africa Opportunities in the Personalized Medicine and Targeted Therapeutics Market 

The Middle East and Africa are also shaping a promising trajectory in the Personalized Medicine and Targeted Therapeutics Market, supported by medical tourism hubs and rising investment in genomic medicine. For instance, the UAE has launched national precision health strategies, while Saudi Arabia has introduced targeted cancer screening as part of its Vision 2030 goals. Datavagyanik indicates that the Personalized Medicine and Targeted Therapeutics Market is gaining momentum in these regions, with an annual growth rate of nearly 10%, driven by a combination of private-public partnerships and a rising burden of non-communicable diseases. 

Personalized Medicine and Targeted Therapeutics Market Segmentation by Therapy Area 

Therapy segmentation is an essential lens to analyze the Personalized Medicine and Targeted Therapeutics Market, revealing a highly diversified landscape. Oncology retains the dominant share, accounting for more than 40% of global revenues in 2024, supported by high unmet clinical needs and advanced biomarker portfolios. For instance, checkpoint inhibitors have achieved a market penetration exceeding 35% within non-small cell lung cancer treatments. Datavagyanik underlines that neurology is the fastest-growing segment, projected to expand at a CAGR of 11% through 2030, supported by a rise in Alzheimer’s and Parkinson’s cases. Additionally, autoimmune diseases are increasingly being targeted by monoclonal antibodies and cell therapies, which are reshaping the Personalized Medicine and Targeted Therapeutics Market through superior efficacy profiles compared to conventional immunosuppressants. 

Personalized Medicine and Targeted Therapeutics Market Segmentation by Technology 

Segmentation by technology illustrates a major transformation in the Personalized Medicine and Targeted Therapeutics Market. For instance, next-generation sequencing platforms account for a significant share of the precision diagnostics landscape, with costs having dropped nearly 90% in the last decade, making them accessible to medium-sized hospitals and regional labs. Datavagyanik notes that advanced bioinformatics tools are also unlocking the potential of multi-omics, allowing a convergence of genomics, proteomics, and metabolomics. This technology convergence is forecast to grow the Personalized Medicine and Targeted Therapeutics demand for integrated analytics platforms by over 15% CAGR. Such advanced technologies are becoming the backbone of truly personalized treatment paradigms. 

Personalized Medicine and Targeted Therapeutics Market Segmentation by End User 

End-user segmentation further clarifies growth dynamics in the Personalized Medicine and Targeted Therapeutics Market. Hospitals continue to lead demand, accounting for more than 50% of revenues, driven by high patient volumes and advanced diagnostic infrastructure. For instance, specialized cancer centers in the US and Europe are implementing tumor boards focused exclusively on targeted therapies, boosting Personalized Medicine and Targeted Therapeutics demand. Datavagyanik also notes that independent diagnostic labs are rapidly scaling their companion diagnostics offerings, driven by the growth in outpatient genetic testing. Homecare and telehealth segments are emerging as additional contributors, enabled by remote sample collection kits and digital consultations, thereby supporting the Personalized Medicine and Targeted Therapeutics Market even outside traditional hospital settings. 

Personalized Medicine and Targeted Therapeutics Market Price Trends 

The Personalized Medicine and Targeted Therapeutics Market has displayed a mixed pricing trend over recent years. For example, while the price of next-generation sequencing has plummeted, some advanced monoclonal antibody therapies and gene therapies continue to command premium pricing above USD 150,000 per treatment course. Datavagyanik observes that price variability is largely explained by the complexity of production, regulatory hurdles, and smaller patient pools in orphan indications. However, increased biosimilar entry and improved manufacturing efficiencies are expected to moderate price growth in the Personalized Medicine and Targeted Therapeutics Market. Such trends will ultimately help expand market penetration across emerging economies. 

Personalized Medicine and Targeted Therapeutics Market Affordability Challenges 

Affordability remains a concern in the Personalized Medicine and Targeted Therapeutics Market, especially as targeted immunotherapies and gene therapies are rolled out. For instance, in oncology, precision treatments have a median price point of USD 80,000–100,000, making them out of reach for many patients in low-income regions. Datavagyanik suggests that payer frameworks need to adapt through value-based reimbursement models to sustain growth in the Personalized Medicine and Targeted Therapeutics Market. Innovative payment models such as outcome-based contracts can ensure equitable access while incentivizing innovation in this fast-evolving field. 

Personalized Medicine and Targeted Therapeutics Market in Pediatric Applications 

Pediatrics is an emerging application area driving additional Personalized Medicine and Targeted Therapeutics demand. For example, precision therapies for pediatric leukemia have achieved remission rates up to 90%, compared to 60% with traditional chemotherapy protocols. Datavagyanik highlights that the pediatric segment, although small in absolute numbers, is growing rapidly at nearly 12% CAGR, driven by public advocacy and funding initiatives targeting rare childhood cancers and genetic metabolic disorders. This trend underscores the Personalized Medicine and Targeted Therapeutics Market’s versatility in addressing patient populations historically underserved by conventional therapeutics. 

Impact of Companion Diagnostics on Personalized Medicine and Targeted Therapeutics Market 

The rising influence of companion diagnostics is another key enabler of growth in the Personalized Medicine and Targeted Therapeutics Market. For instance, these tests have increased treatment-matching success rates by more than 45%, improving patient outcomes while reducing costs for healthcare systems. Datavagyanik emphasizes that companion diagnostics revenues themselves are projected to surpass USD 12 billion by 2026, creating an interconnected ecosystem where diagnostics and therapeutics move in tandem. This synergy is critical to fulfilling the promise of the Personalized Medicine and Targeted Therapeutics Market and is expected to shape its future growth pattern. 

Regional Pricing Analysis within the Personalized Medicine and Targeted Therapeutics Market 

A regional analysis of pricing reveals significant disparities in the Personalized Medicine and Targeted Therapeutics Market. For example, North America has some of the world’s highest pricing structures due to advanced insurance reimbursements and higher R&D costs, while Asia Pacific demonstrates a more moderate pricing strategy to achieve mass-scale penetration. Datavagyanik points out that personalized oncology treatments in the US can cost double compared to similar regimens in Japan, driven by differences in regulatory approval pathways and intellectual property protections. As price pressures build, manufacturers are expected to tailor regional strategies to balance affordability and innovation in the Personalized Medicine and Targeted Therapeutics Market. 

Digital Health Integration in the Personalized Medicine and Targeted Therapeutics Market 

Digital health is accelerating growth across the Personalized Medicine and Targeted Therapeutics Market by enabling more efficient treatment pathways. For instance, clinical decision-support tools integrated with EHR systems are helping clinicians match patients to the most appropriate targeted therapies in real time. Datavagyanik notes that digital integration can reduce hospital readmissions by 20%, directly enhancing the Personalized Medicine and Targeted Therapeutics demand by ensuring adherence and improving outcomes. As telemedicine and remote monitoring gain popularity, their synergy with precision therapeutics will continue to transform the market’s delivery model. 

Future Outlook for Price Optimization in the Personalized Medicine and Targeted Therapeutics Market 

Datavagyanik anticipates that the Personalized Medicine and Targeted Therapeutics Market will gradually stabilize its pricing through innovations in manufacturing, automation, and strategic collaborations. For example, the introduction of AI-driven production pipelines and modular manufacturing facilities could cut costs by up to 30%, improving affordability. These shifts are expected to encourage broader adoption of personalized therapies even in lower-income settings, sustaining Personalized Medicine and Targeted Therapeutics demand. Furthermore, as patent cliffs approach for certain biologics, biosimilars will play a crucial role in reshaping the price environment in the Personalized Medicine and Targeted Therapeutics Market. 

Segmentation Outlook in the Personalized Medicine and Targeted Therapeutics Market 

Overall, segmentation by therapy area, technology, and end-user profiles demonstrates that the Personalized Medicine and Targeted Therapeutics Market is not a monolith but a highly dynamic, segmented domain. For instance, precision cardiology is emerging with therapies targeting familial hypercholesterolemia, while autoimmune disease applications are gaining new approvals for gene-based interventions. Datavagyanik projects that segmentation will only become more granular, with specialized treatment centers developing hyper-focused programs for unique patient groups. This detailed segmentation will be critical in maximizing the impact and patient reach of the Personalized Medicine and Targeted Therapeutics Market. 

 

Leading Players in the Personalized Medicine and Targeted Therapeutics Market 

The Personalized Medicine and Targeted Therapeutics Market is dominated by a combination of established pharmaceutical giants and nimble biotech innovators. These market players are shaping the landscape across therapy areas and geographies, leveraging deep pipelines and diagnostic ecosystems. 

Roche – Precision Oncology and Companion Diagnostics 

Roche leads the Personalized Medicine and Targeted Therapeutics Market, holding an estimated 18% share, propelled by its Hemlibra (emicizumab) and Tecentriq (atezolizumab) immuno-oncology franchise. For instance, Tecentriq combined with companion PD-L1 diagnostics has achieved double-digit market penetration in first-line bladder cancer treatment. Roche’s Foundation Medicine subsidiary further bolsters its market reach by offering comprehensive genomic profiling tests, enriching the Personalized Medicine and Targeted Therapeutics Market ecosystems with real-world data. 

Novartis – Gene Therapy and Rare Disease Innovations 

Novartis captures close to 12% share in the Personalized Medicine and Targeted Therapeutics Market, due to its pioneering gene therapy Zolgensma for spinal muscular atrophy and targeted B-cell lymphoma drug Kymriah. These therapies exemplify the trend toward single-administration cures in rare and pediatric patient groups. Kymriah, for example, has seen over 60% remission rates in refractory pediatric leukemia, underlining Novartis’s dominance in the Personalized Medicine and Targeted Therapeutics Market. 

Pfizer – Immunotherapy and Genomic Testing Partnerships 

Accounting for nearly 9% of the Personalized Medicine and Targeted Therapeutics Market, Pfizer has strengthened its position through Imfinzi (durvalumab) and a strategic diagnostic tie-up with Foundation Medicine. Imfinzi, particularly when used with molecular companion tests for PD-L1 expression, has garnered usage in over 25,000 advanced NSCLC patients. Their collaboration to integrate genomic insights into cancer pipelines highlights Pfizer’s growing influence on both therapeutic and diagnostic fronts of the Personalized Medicine and Targeted Therapeutics Market. 

AstraZeneca – Targeted Therapeutics in Lung and Breast Cancer 

AstraZeneca holds roughly 8% of the Personalized Medicine and Targeted Therapeutics Market with flagship drugs like Tagrisso (osimertinib) for EGFR-mutant lung cancer and Lynparza (olaparib) for BRCA-mutated breast and ovarian cancer. Tagrisso is now prescribed to more than 70,000 patients globally, pushing AstraZeneca’s revenue share in the Personalized Medicine and Targeted Therapeutics Market. Lynparza’s expanding use across multiple tumor types emphasizes AstraZeneca’s deep commitment to targeted therapeutics. 

Gilead Sciences – CAR-T Therapies Expansion 

Gilead Sciences commands approximately 7% of the Personalized Medicine and Targeted Therapeutics Market via its cell therapy division Kite Pharma. Yescarta and Tecartus, both autologous CAR-T therapies, have demonstrated over 80% overall response rates in certain lymphoma indications, driving rapid market uptake. The rollout of Yescarta across 20+ countries is boosting Gilead’s presence in the Personalized Medicine and Targeted Therapeutics Market. 

Bristol Myers Squibb – Immune Modulation and Precision Oncology 

With nearly 6% market share, Bristol Myers Squibb anchors its position in the Personalized Medicine and Targeted Therapeutics Market through Opdivo (nivolumab) and Yervoy (ipilimumab), supported by companion diagnostic integration. Opdivo’s usage in PD-L1-positive melanoma and renal cell carcinoma has accelerated adoption rates. Furthermore, the 2025 approval of Breyanzi (lisocabtagene maraleucel) CAR-T therapy in lymphoma reaffirms BMS’s expanding investment in the Personalized Medicine and Targeted Therapeutics Market. 

Amgen – Bioengineered Antibodies and Bone Health 

Amgen contributes around 5% of the Personalized Medicine and Targeted Therapeutics Market via drugs like Repatha (evolocumab), a PCSK9 inhibitor for hypercholesterolemia, and Lumakras (sotorasib), a KRAS G12C inhibitor for lung cancer. Repatha’s penetration into cardiovascular precision medicine and Lumakras’s niche uptake highlight Amgen’s dual targeting of metabolic and oncologic precision therapy niches within the Personalized Medicine and Targeted Therapeutics Market. 

Regeneron – Genomic-Driven Blockbuster Antibodies 

Regeneron takes about 4% share of the Personalized Medicine and Targeted Therapeutics Market, largely driven by Dupixent (dupilumab) in atopic dermatitis and asthma, which incorporates genetic biomarkers for patient stratification. Greater than 60% of Dupixent’s global prescriptions are guided by atopic biomarker profiling, demonstrating Regeneron’s ability to drive Personalized Medicine and Targeted Therapeutics demand through genomic insights. 

Other Emerging Players 

Besides these major players, several specialized biotech companies — such as Bluebird Bio (cell/gene therapies), Illumina (sequencing platforms), and Guardant Health (liquid biopsy) — are collectively capturing roughly 20% of the Personalized Medicine and Targeted Therapeutics Market. Illumina’s NovaSeq platform has become central to precision oncology pipelines, while Guardant’s non-invasive cancer detection tests now inform treatment decisions in more than 3,500 hospitals. 

 

Comparative Overview of Top Market Players 

Company	Estimated Market Share	Key Products/Services
Roche	~18%	Hemlibra, Tecentriq, Foundation Medicine genomic profiling
Novartis	~12%	Zolgensma, Kymriah
Pfizer	~9%	Imfinzi, Foundation Medicine partnership
AstraZeneca	~8%	Tagrisso, Lynparza
Gilead Sciences (Kite)	~7%	Yescarta, Tecartus
Bristol Myers Squibb	~6%	Opdivo, Yervoy, Breyanzi
Amgen	~5%	Repatha, Lumakras
Regeneron	~4%	Dupixent
Biotech & Diagnostics Players	~20%	Bluebird Bio, Illumina, Guardant Health, etc.

 

Recent Developments in the Personalized Medicine and Targeted Therapeutics Market 

April 15, 2025 – Roche announced pivotal Phase III data showing Tecentriq’s survival benefit increased by 20% when combined with a new genomic companion diagnostic. This milestone is set to reinforce Roche’s dominant share in the Personalized Medicine and Targeted Therapeutics Market. 

May 8, 2025 – Novartis received regulatory clearance for Kymriah in pediatric glioblastoma based on biomarker-driven remission data, expanding its pediatric oncology footprint in the Personalized Medicine and Targeted Therapeutics Market. 

June 3, 2025 – Pfizer and Illumina formalized a strategic alliance to co-develop a next-gen sequencing-based liquid biopsy platform. This collaboration is expected to capture incremental Personalized Medicine and Targeted Therapeutics demand across oncology and rare disease testing. 

June 20, 2025 – AstraZeneca opened a new precision medicine research center in Shanghai focusing on EGFR-resistant lung cancer, signaling Asia Pacific expansion in the Personalized Medicine and Targeted Therapeutics Market. 

June 28, 2025 – Gilead’s Kite Pharma initiated Phase II trials for a novel BCMA-targeted CAR-T therapy in multiple myeloma, indicating bold therapeutic pipeline expansion within the Personalized Medicine and Targeted Therapeutics Market. 

 

Key Insights that the Personalized Medicine and Targeted Therapeutics  Market analysis report presents are:

• Personalized Medicine and Targeted Therapeutics  Market revenue and demand by countries
• Break-down of the Personalized Medicine and Targeted Therapeutics  Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Personalized Medicine and Targeted Therapeutics  Market competitive scenario, market share analysis
• Personalized Medicine and Targeted Therapeutics  Market business opportunity analysis

Global and Country-Wise Personalized Medicine and Targeted Therapeutics  Market Statistics

• Global and Country-Wise Personalized Medicine and Targeted Therapeutics  Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Personalized Medicine and Targeted Therapeutics  Market Trend Analysis
• Global and Country-Wise Personalized Medicine and Targeted Therapeutics  Market Business Opportunity Assessment